From high‑content screens to complex models, AI-empowered solution is changing how scientists interpret imaging data.This FAQ walks through how AI‑powered image analysis speeds up review, reduces variability, and reveals subtle phenotypes that manual methods often miss. Read the FAQ: https://bit.ly/3QPZbNu
Danaher Life Sciences
Biotechnology Research
Framingham, Massachusetts 49,710 followers
Innovation at the speed of life
About us
The Life Sciences companies of Danaher integrate the deep scientific expertise of our individual operating companies with the robust engineering know-how of the Danaher Business System to create innovative workflows that significantly bend the drug development time curve. Every day, scientists around the world are working to understand the causes of disease, develop new therapies and vaccines, and test new drugs. These life science companies make this leading-edge scientific research possible. Our capabilities extend beyond research to power the creation of biopharmaceuticals, cell and gene therapies, and other breakthrough treatments to advance patient health and improve treatment outcomes. Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. We partner with customers across the globe to help them solve their most complex challenges, architecting solutions that bring the power of science to life. Our global teams are pioneering what’s next across Life Sciences, Diagnostics, Biotechnology and beyond.
- Website
-
https://lifesciences.danaher.com
External link for Danaher Life Sciences
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Framingham, Massachusetts
- Type
- Public Company
Updates
-
With a full house at American Society of Gene & Cell Therapy, our lunch symposium, “Manufacturing the Future: The Path from N=1 to N=Many,” brought thoughtful discussion on how to scale personalized mRNA base editing. We’re grateful to our speakers Kiran Musunuru, MD, PhD, MPH, ML, Patricia Musolino M.D, Ph.D, Tom Foti, Sadik Kassim, Venkata Shravan K Indurthi, Scott Ripley and all the participants for the engaging energy in the room and the valuable exchanges after the presentations, showcasing how aligned platforms, partnerships, and innovation across the ecosystem can help move N‑of‑1 breakthroughs toward impact for many patients. Stay tuned for the on‑demand presentation.
-
-
-
-
-
+1
-
-
As AAV and genomic medicine pipelines expand, analytics need to move faster, not become a bottleneck. Brandon Bates highlights how SCIEX platforms, combined with Beckman Coulter Life Sciences automation, help teams scale high-throughput characterization while maintaining CMC and regulatory readiness. Visit us at #Booth1337 to continue the discussion, or learn more at https://bit.ly/4exwjmZ
-
At American Society of Gene & Cell Therapy 2026 this week, Ashley Jacobi from Integrated DNA Technologies and Max Sellman from Aldevron are talking with CRISPR teams about building a reliable path from discovery to the clinic with integrated solutions. They show how high‑quality RUO materials and scalable GMP manufacturing can create a more connected bench‑to‑patient journey. Join our lunch symposium today to hear experts discuss scaling from N=1 to platform-driven solutions: https://bit.ly/4dd6pSW
-
From the floor at #ASGCT2026, Greg Milosevich reflects on what Baby KJ’s journey and the recognition of this work with the ASGCT Catalyst Award means for patients and for the CGT community, showing how a connected ecosystem of technologies, expertise, and partnerships can help more therapies move from a single urgent need to treatments at scale. Progress in this field has never been individual. It is collective. Join us on Thursday for our lunch symposium at American Society of Gene & Cell Therapy, where a panel of experts will explore how we move from N=1 to N=many in cell and gene therapy. Save your seat at https://bit.ly/4wqMVmT
-
It’s a powerful reminder of how far cell and gene therapy has come and what’s still possible when teams across research, manufacturing, and clinical care work as one. Congratulations to all the teams recognized in this work. We’re honored to be part of this journey, using our portfolio and ecosystem to help turn moments like Baby KJ’s from N=1 breakthroughs into futures for many patients. Aldevron, Integrated DNA Technologies
Baby KJ was born with a rare, potentially fatal genetic disease with limited treatment options and significant uncertainty. In response, the world's first personalized CRISPR‑based therapy was designed, manufactured, and administered to him in record time. That effort is why teams from Children's Hospital of Philadelphia, Penn Medicine, University of Pennsylvania Health System, Innovative Genomics Institute, and Danaher Corporation received the ASGCT Catalyst Award this week at #ASGCT2026. The work moved forward because people across medicine, academia, and industry stayed aligned on one outcome: turning a one‑of‑a‑kind scientific idea into a treatment for a child who needed it now. Doing that required coordination across research, manufacturing, and clinical care, with no precedent and no margin for delay. Danaher Life Sciences businesses Aldevron and Integrated DNA Technologies manufactured key components of this highly complex, personalized gene editing therapy at speed, with Aldevron producing the final drug product. Congratulations to the teams whose collaboration made this possible, and to the broader cell and gene therapy community advancing what can be delivered when expertise, scale, and urgency come together.
-
-
LNP programs often stall when formulation and analytics are disconnected. Live at American Society of Gene & Cell Therapy, Scott Ripley from Cytiva and Amy Henrickson, PhD from Beckman Coulter Life Sciences share how reproducible LNP design, combined with robust size and encapsulation data, can give preclinical teams a clearer, more confident path to advance RNA and genomic medicine candidates. Continue the conversation with us at #Booth1337 or learn more at https://bit.ly/4exwjmZ
-
Join us at American Society of Gene & Cell Therapy in Booth 1337! We are showcasing how platform approaches across the manufacturing workflow are turning complex interventions into scalable genetic medicines. Learn more about our solutions: https://bit.ly/4exwjmZ Save your seat at the Lunch Symposium: https://bit.ly/4dd6pSW Aldevron, Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, SCIEX
-
-
Join Novartis and leading peers from Boston’s pharma and biotech community to explore practical ways to scale oligonucleotide R&D using LC‑MS/MS, advanced separations, automated MS analytics and digital platforms for characterization, impurity profiling, data management and compliance. Learn more and register: https://lnkd.in/epWuzqXD
-
-
See you next week at American Society of Gene & Cell Therapy! Join us at #Booth1337 explore how platform approaches and connected ecosystems across scalable manufacturing, advanced analytics and evolving regulatory paradigms can turn bespoke interventions into accessible genetic medicines. Learn more: https://bit.ly/4exwjmZ Save your seat at the Lunch Symposium: https://bit.ly/4dd6pSW Aldevron, Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, SCIEX